Original Literature | Model OverView |
---|---|
Publication
Title
Cytokines, PGE2 and endotoxic fever: a re-assessment.
Affiliation
Department of Physiology, College of Medicine, The University of Tennessee,Health Science Center, Memphis, 38163, USA. blatteis@physio1.utmem.edu
Abstract
The innate immune system serves as the first line of host defense against thedeleterious effects of invading infectious pathogens. Fever is the hallmarkamong the defense mechanisms evoked by the entry into the body of suchpathogens. The conventional view of the steps that lead to fever production isthat they begin with the biosynthesis of pyrogenic cytokines by mononuclearphagocytes stimulated by the pathogens, their release into the circulation andtransport to the thermoregulatory center in the preoptic area (POA) of theanterior hypothalamus, and their induction there of cyclooxygenase(COX)-2-dependent prostaglandin (PG)E(2), the putative final mediator of thefebrile response. But data accumulated over the past 5 years have graduallychallenged this classical concept, due mostly to the temporal incompatibility ofthe newer findings with this concatenation of events. Thus, the former studiesgenerally overlooked that the production of cytokines and the transduction oftheir pyrogenic signals into fever-mediating PGE(2) proceed at relatively slowrates, significantly slower certainly than the onset latency of fever producedby the i.v. injection of bacterial endotoxic lipopolysaccharides (LPS). Here, wereview the conflicts between the earlier and the more recent findings andsummarize new data that reconcile many of the contradictions. A unified modelbased on these data explicating the generation and maintenance of the febrileresponse is presented. It postulates that the steps in the production of LPSfever occur in the following sequence: the immediate activation by LPS of thecomplement (C) cascade, the stimulation by the anaphylatoxic C component C5a ofKupffer cells, their consequent, virtually instantaneous release of PGE(2), itsexcitation of hepatic vagal afferents, their transmission of the induced signalsto the POA via the ventral noradrenergic bundle, and the activation by the thus,locally released norepinephrine (NE) of neural alpha(1)- and glialalpha(2)-adrenoceptors. The activation of the first causes an immediate,PGE(2)-independent rise in core temperature (T(c)) [the early phase of fever; anantioxidant-sensitive PGE(2) rise, however, accompanies this first phase], andof the second a delayed, PGE(2)-dependent T(c) rise [the late phase of fever].Meanwhile-generated pyrogenic cytokines and their consequent upregulation ofblood-brain barrier cells COX-2 also contribute to the latter rise. Theconsecutive steps that initiate the febrile response to LPS would now appear,therefore, to occur in an order different than conceived originally.
PMID
15967158
|
Entity
TNF-alpha
--
MO000000289
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m230
10
infinite
0
InterPro | IPR003636 |
TRANSPATH | MO000000289 |
--
COX-2
--
MO000017266
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m2122
10
infinite
0
InterPro | IPR002016 |
TRANSPATH | MO000017266 |
--
COX-1
--
MO000018979
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m3590
10
infinite
0
InterPro | IPR002016 |
TRANSPATH | MO000018979 |
--
LPS:LBP:CD14
--
MO000021929
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m6255
10
infinite
0
TRANSPATH | MO000021929 |
--
PGE2
--
MO000021939
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m346644
10
infinite
0
TRANSPATH | MO000021939 |
--
--
e1
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane
--
--
--
csml-variable:Double
m1
0
infinite
0
--
--
e10
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytosol
--
--
--
csml-variable:Double
m10
0
infinite
0
--
Il-1:IL-6R
--
e11
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m11
0
infinite
0
--
IL-1beta R
--
e12
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m12
0
infinite
0
--
IL-1beta:IL-1betaR
--
e13
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m13
0
infinite
0
--
TNF-alphaR
--
e14
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m14
0
infinite
0
--
TNF-alpha:TNF-alphaR
--
e15
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m15
0
infinite
0
--
IFN-gammaR
--
e16
cso30:c:Protein
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m16
0
infinite
0
--
IFN-gamma:IFN-gammaR
--
e17
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m17
0
infinite
0
--
Cox-2
--
e18
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m18
0
infinite
0
--
mPGES-1
--
e19
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m19
0
infinite
0
--
--
e2
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m2
0
infinite
0
--
cPLA2
--
e20
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m20
0
infinite
0
--
cPLA2{active}
--
e21
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m21
0
infinite
0
--
C3b
--
e22
cso30:c:Protein
cso30:i:CC_Extracellular
--
csml-variable:Double
m22
0
infinite
0
--
iC3b
--
e23
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m23
0
infinite
0
--
C3b
--
e24
cso30:c:Protein
cso30:i:CC_Extracellular
--
csml-variable:Double
m24
0
infinite
0
--
iC3b
--
e25
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m25
0
infinite
0
--
Phosphoinositide
--
e26
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m26
0
infinite
0
--
PI-PLC{active}
--
e27
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m27
0
infinite
0
--
Arachidonic acid
--
e28
cso30:c:SmallMolecule
cso30:i:CC_Cytosol
--
csml-variable:Double
m28
0
infinite
0
--
PI-PLC
--
e29
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m29
0
infinite
0
--
--
e3
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
--
csml-variable:Double
m3
0
infinite
0
--
Aspirin
--
e30
cso30:c:Protein
cso30:i:CC_Extracellular
--
csml-variable:Double
m30
0
infinite
0
--
mPGES-1
--
e31
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m31
0
infinite
0
--
pyrogens
--
e32
cso30:c:Protein
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m32
0
infinite
0
--
Gadolinium chloride
--
e33
cso30:c:SmallMolecule
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m33
0
infinite
0
--
CVF
--
e34
cso30:c:SmallMolecule
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m34
0
infinite
0
--
PGE2 anti serum
--
e35
cso30:c:Protein
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m35
0
infinite
0
--
serum c
--
e36
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m36
0
infinite
0
--
NE
--
e37
cso30:c:Protein
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m37
0
infinite
0
--
NE receptor
--
e38
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
csml-variable:Double
m38
0
infinite
0
--
NE:receptor
--
e39
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m39
0
infinite
0
--
--
e4
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m4
0
infinite
0
--
TLR4-MD-2
--
e5
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m5
0
infinite
0
--
--
e50
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelopeLumen
--
--
--
csml-variable:Double
m50
0
infinite
0
--
--
e51
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearPore
--
--
--
csml-variable:Double
m51
0
infinite
0
--
--
e52
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearInnerMembrane
--
--
--
csml-variable:Double
m52
0
infinite
0
--
--
e53
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearLumen
--
--
--
csml-variable:Double
m53
0
infinite
0
--
--
e54
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearOuterMembrane
--
--
--
csml-variable:Double
m54
0
infinite
0
--
--
e55
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleus
--
--
--
csml-variable:Double
m55
0
infinite
0
--
--
e56
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleoplasm
--
--
--
csml-variable:Double
m56
0
infinite
0
--
--
e57
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearBody
--
--
--
csml-variable:Double
m57
0
infinite
0
--
--
e58
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleolus
--
--
--
csml-variable:Double
m58
0
infinite
0
--
--
e59
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelope
--
--
--
csml-variable:Double
m59
0
infinite
0
--
TLR4:LPS
--
e6
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m6
0
infinite
0
--
--
e60
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Chromatin
--
--
--
csml-variable:Double
m60
0
infinite
0
--
--
e61
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearChromosome
--
--
--
csml-variable:Double
m61
0
infinite
0
--
--
e62
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearCentromere
--
--
--
csml-variable:Double
m62
0
infinite
0
--
--
e7
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell
--
--
--
csml-variable:Double
m7
0
infinite
0
--
--
e8
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell_WithoutCellWall_
--
--
--
csml-variable:Double
m8
0
infinite
0
--
--
e9
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytoplasm
--
--
--
csml-variable:Double
m9
0
infinite
0
--
p1
p1
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c1 : 1
stoichiometry:c2 : 1
stoichiometry:c3 : 1
m155666*m3985*0.1
nodelay
--
0
PMID:15967158,15051069 For example, PAMPs produced by cellwall components of Gram-negative bacteria (LPS) are recognized by TLR4; it involves the binding of LPS to a serum protein, lipopolysaccharide-binding protein (LPB), which in turn binds to membrane CD14, which transfers the complex to TLR4 in an MD-2-dependent manner
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c22 : 1
stoichiometry:c23 : 1
stoichiometry:c24 : 1
m1639*m16*0.1
nodelay
--
0
PMID:15967158 They are then released into the bloodstream and transported to sites in or close to the POA that react to their stimulation by selectively expressing COX-2 and mPGES-1.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c27 : 1
stoichiometry:c31 : 1
m11*0.1
nodelay
--
0
PMID:15967158 They are then released into the bloodstream and transported to sites in or close to the POA that react to their stimulation by selectively expressing COX-2 and mPGES-1.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c28 : 1
stoichiometry:c32 : 1
m13*0.1
nodelay
--
0
PMID:15967158 They are then released into the bloodstream and transported to sites in or close to the POA that react to their stimulation by selectively expressing COX-2 and mPGES-1.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c33 : 1
stoichiometry:c37 : 1
m17*0.1
nodelay
--
0
PMID:15967158 They are then released into the bloodstream and transported to sites in or close to the POA that react to their stimulation by selectively expressing COX-2 and mPGES-1.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c34 : 1
stoichiometry:c38 : 1
m15*0.1
nodelay
--
0
PMID:15967158 They are then released into the bloodstream and transported to sites in or close to the POA that react to their stimulation by selectively expressing COX-2 and mPGES-1.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c35 : 1
stoichiometry:c39 : 1
m11*0.1
nodelay
--
0
PMID:15967158 They are then released into the bloodstream and transported to sites in or close to the POA that react to their stimulation by selectively expressing COX-2 and mPGES-1.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c36 : 1
stoichiometry:c40 : 1
m13*0.1
nodelay
--
0
PMID:15967158 They are then released into the bloodstream and transported to sites in or close to the POA that react to their stimulation by selectively expressing COX-2 and mPGES-1.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c41 : 1
stoichiometry:c42 : 1
m6*0.1
nodelay
--
0
PMID: 15967158,9748570,9880592,12957837,9917869,10578230 In support, LPS, like IL-1beta, induces these enzymes in endothelial cells of the cerebral microvasculature, including in the OVLT, the choroid plexi and the leptomeninges
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c43 : 1
stoichiometry:c44 : 1
m6*0.1
nodelay
--
0
PMID: 15967158,9748570,9880592,12957837,9917869,10578230 In support, LPS, like IL-1beta, induces these enzymes in endothelial cells of the cerebral microvasculature, including in the OVLT, the choroid plexi and the leptomeninges
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c45 : 1
stoichiometry:c46 : 1
stoichiometry:c47 : 1
m6*m20*0.1
nodelay
--
0
PMID: 15967158,8027674,12376404,14977603 Indeed, the activation by LPS of group IV cytosolic phospholipase (cPL)A2 is significantly delayed in vitro and in vivo
p2
p2
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c4 : 1
stoichiometry:c5 : 1
stoichiometry:c6 : 1
m6254*m2828*0.1
nodelay
--
0
PMID:15967158,15051069 For example, PAMPs produced by cellwall components of Gram-negative bacteria (LPS) are recognized by TLR4; it involves the binding of LPS to a serum protein, lipopolysaccharide-binding protein (LPB), which in turn binds to membrane CD14, which transfers the complex to TLR4 in an MD-2-dependent manner
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c48 : 1
stoichiometry:c49 : 1
m13*0.1
nodelay
--
0
PMID: 15967158,7664696,8193936 the expression of c-fos in the nucleus of the solitary tract (NTS, the primary projection area of the vagus nerves) is enhanced after i.v. and i.p. IL-1beta and i.v. LPS
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c50 : 1
stoichiometry:c51 : 1
m6*0.1
nodelay
--
0
PMID: 15967158,7664696,8193936 the expression of c-fos in the nucleus of the solitary tract (NTS, the primary projection area of the vagus nerves) is enhanced after i.v. and i.p. IL-1beta and i.v. LPS
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c52 : 1
stoichiometry:c53 : 1
m6*0.1
nodelay
--
0
PMID: 15967158 Together, these data, plus others not described, thus substantiate the notion that circulating LPS arriving in the liver could activate Kc to produce and release TNFalpha, IL-1beta and IL-6
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c55 : 1
stoichiometry:c56 : 1
m6*0.1
nodelay
--
0
PMID: 15967158 Together, these data, plus others not described, thus substantiate the notion that circulating LPS arriving in the liver could activate Kc to produce and release TNFalpha, IL-1beta and IL-6
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c54 : 1
stoichiometry:c57 : 1
m6*0.1
nodelay
--
0
PMID: 15967158 Together, these data, plus others not described, thus substantiate the notion that circulating LPS arriving in the liver could activate Kc to produce and release TNFalpha, IL-1beta and IL-6
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c58 : 1
stoichiometry:c59 : 1
m93309*0.1
nodelay
--
0
PMID: 15967158 Together, these data, plus others not described, thus substantiate the notion that circulating LPS arriving in the liver could activate Kc to produce and release TNFalpha, IL-1beta and IL-6
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c60 : 1
stoichiometry:c61 : 1
m93248*0.1
nodelay
--
0
PMID: 15967158 Together, these data, plus others not described, thus substantiate the notion that circulating LPS arriving in the liver could activate Kc to produce and release TNFalpha, IL-1beta and IL-6
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c62 : 1
stoichiometry:c63 : 1
m93364*0.1
nodelay
--
0
PMID: 15967158 Together, these data, plus others not described, thus substantiate the notion that circulating LPS arriving in the liver could activate Kc to produce and release TNFalpha, IL-1beta and IL-6
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c66 : 1
stoichiometry:c67 : 1
m6*0.1
nodelay
--
0
PMID: 15967158 Indeed, the i.v. administration of LPS triggers within 2 min the C cascade via the alternative pathway, resulting in the production in blood of C4a, C3a and C5a and of surface-bound and fluid-phase C3b and iC3b
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c68 : 1
stoichiometry:c69 : 1
m6*0.1
nodelay
--
0
PMID: 15967158 Indeed, the i.v. administration of LPS triggers within 2 min the C cascade via the alternative pathway, resulting in the production in blood of C4a, C3a and C5a and of surface-bound and fluid-phase C3b and iC3b
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c7 : 1
stoichiometry:c8 : 1
stoichiometry:c9 : 1
m6438*m3961*0.1
nodelay
--
0
PMID:15967158,15051069 For example, PAMPs produced by cellwall components of Gram-negative bacteria (LPS) are recognized by TLR4; it involves the binding of LPS to a serum protein, lipopolysaccharide-binding protein (LPB), which in turn binds to membrane CD14, which transfers the complex to TLR4 in an MD-2-dependent manner
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c70 : 1
stoichiometry:c71 : 1
m6*0.1
nodelay
--
0
PMID: 15967158 Indeed, the i.v. administration of LPS triggers within 2 min the C cascade via the alternative pathway, resulting in the production in blood of C4a, C3a and C5a and of surface-bound and fluid-phase C3b and iC3b
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c72 : 1
stoichiometry:c74 : 1
m6*0.1
nodelay
--
0
PMID: 15967158 Indeed, the i.v. administration of LPS triggers within 2 min the C cascade via the alternative pathway, resulting in the production in blood of C4a, C3a and C5a and of surface-bound and fluid-phase C3b and iC3b
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c73 : 1
stoichiometry:c75 : 1
m6*0.1
nodelay
--
0
PMID: 15967158 Indeed, the i.v. administration of LPS triggers within 2 min the C cascade via the alternative pathway, resulting in the production in blood of C4a, C3a and C5a and of surface-bound and fluid-phase C3b and iC3b
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c76 : 1
stoichiometry:c78 : 1
m6*0.1
nodelay
--
0
PMID: 15967158 Indeed, the i.v. administration of LPS triggers within 2 min the C cascade via the alternative pathway, resulting in the production in blood of C4a, C3a and C5a and of surface-bound and fluid-phase C3b and iC3b
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c77 : 1
stoichiometry:c79 : 1
m6*0.1
nodelay
--
0
PMID: 15967158 Indeed, the i.v. administration of LPS triggers within 2 min the C cascade via the alternative pathway, resulting in the production in blood of C4a, C3a and C5a and of surface-bound and fluid-phase C3b and iC3b
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c80 : 1
stoichiometry:c82 : 1
stoichiometry:c111 : 1
stoichiometry:c81 : 1
m26*m27*0.1
nodelay
--
0
PMID: 15967158 PGE2, under these conditions, could be generated via the hydrolysis of membrane-associated phosphoinositide (PI, which has a high arachydonoyl chain content) by PI-specific phospholipase C (PI-PLC) PMID: 15967158,5284360 Vane demonstrated that aspirin blocks prostaglandin synthesis
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c83 : 1
stoichiometry:c84 : 1
m27*0.1
nodelay
--
0
PMID: 15967158 indeed, arachidonic acid (AA) liberation by PI-PLC is 10-fold more rapid (within seconds) than that mediated by cPLA2 PMID: 15967158 Moreover, PI-PLC is reportedly activated by C, but not by LPS or IL-1beta, and the subsequent conversion of this AA to PGE2 is catalyzed by COX-1
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c85 : 1
stoichiometry:c86 : 1
m21*0.1
nodelay
--
0
PMID: 15967158, indeed, arachidonic acid (AA) liberation by PI-PLC is 10-fold more rapid (within seconds) than that mediated by cPLA2
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c87 : 1
stoichiometry:c88 : 1
stoichiometry:c89 : 1
m22*m29*0.1
nodelay
--
0
PMID: 15967158 Moreover, PI-PLC is reportedly activated by C, but not by LPS or IL-1beta, and the subsequent conversion of this AA to PGE2 is catalyzed by COX-1
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c90 : 1
stoichiometry:c91 : 1
stoichiometry:c92 : 1
m23*m29*0.1
nodelay
--
0
PMID: 15967158 Moreover, PI-PLC is reportedly activated by C, but not by LPS or IL-1beta, and the subsequent conversion of this AA to PGE2 is catalyzed by COX-1
p2
p4
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c10 : 1
stoichiometry:c11 : 1
stoichiometry:c12 : 1
stoichiometry:c64 : 1
stoichiometry:c65 : 1
m5*m6255*0.1
nodelay
--
0
PMID:15967158,15051069 For example, PAMPs produced by cellwall components of Gram-negative bacteria (LPS) are recognized by TLR4; it involves the binding of LPS to a serum protein, lipopolysaccharide-binding protein (LPB), which in turn binds to membrane CD14, which transfers the complex to TLR4 in an MD-2-dependent manner
p38
p40
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c93 : 1
stoichiometry:c94 : 1
stoichiometry:c95 : 1
m44674*m29*0.1
nodelay
--
0
PMID: 15967158 Moreover, PI-PLC is reportedly activated by C, but not by LPS or IL-1beta, and the subsequent conversion of this AA to PGE2 is catalyzed by COX-1
p38
p41
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c96 : 1
stoichiometry:c97 : 1
stoichiometry:c98 : 1
m13505*m29*0.1
nodelay
--
0
PMID: 15967158 Moreover, PI-PLC is reportedly activated by C, but not by LPS or IL-1beta, and the subsequent conversion of this AA to PGE2 is catalyzed by COX-1
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c99 : 1
stoichiometry:c100 : 1
stoichiometry:c101 : 1
m24*m29*0.1
nodelay
--
0
PMID: 15967158 Moreover, PI-PLC is reportedly activated by C, but not by LPS or IL-1beta, and the subsequent conversion of this AA to PGE2 is catalyzed by COX-1
p38
p43
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c102 : 1
stoichiometry:c103 : 1
stoichiometry:c104 : 1
m12280*m29*0.1
nodelay
--
0
PMID: 15967158 Moreover, PI-PLC is reportedly activated by C, but not by LPS or IL-1beta, and the subsequent conversion of this AA to PGE2 is catalyzed by COX-1
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c105 : 1
stoichiometry:c106 : 1
stoichiometry:c107 : 1
m25*m29*0.1
nodelay
--
0
PMID: 15967158 Moreover, PI-PLC is reportedly activated by C, but not by LPS or IL-1beta, and the subsequent conversion of this AA to PGE2 is catalyzed by COX-1
p45
p45
cso30:i:ME_UnknownProduction
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c108 : 1
stoichiometry:c110 : 1
stoichiometry:c112 : 1
stoichiometry:c109 : 1
m28*m3590*0.1
nodelay
--
0
PMID: 15967158 Moreover, PI-PLC is reportedly activated by C, but not by LPS or IL-1beta, and the subsequent conversion of this AA to PGE2 is catalyzed by COX-1 PMID: 15967158,5284360 Vane demonstrated that aspirin blocks prostaglandin synthesis
p46
p46
cso30:i:ME_UnknownProduction
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c113 : 1
stoichiometry:c122 : 1
stoichiometry:c114 : 1
m19*0.1
nodelay
--
0
PMID: 15967158,11113021,11113018 Thus, it is now generally believed that cyclooxygenase (COX)-2 and microsomal prostaglandin E synthase (mPGES)-1 selectively induced by pyrogenic cytokines catalyze its production, and that it acts in the preoptic-anterior hypothalamus (POA), the brain site of the primary thermoregulatory controller PMID: 15967158 The second step of the conventional sequence asserts that the synthesis of PGE2 is effected in the POA via catalysis by COX-2 and mPGES-1 PMID: 15967158,5284360 Vane demonstrated that aspirin blocks prostaglandin synthesis
p46
p47
cso30:i:ME_UnknownProduction
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c115 : 1
stoichiometry:c121 : 1
stoichiometry:c116 : 1
m18*0.1
nodelay
--
0
PMID: 15967158,11113021,11113018 Thus, it is now generally believed that cyclooxygenase (COX)-2 and microsomal prostaglandin E synthase (mPGES)-1 selectively induced by pyrogenic cytokines catalyze its production, and that it acts in the preoptic-anterior hypothalamus (POA), the brain site of the primary thermoregulatory controller PMID: 15967158 The second step of the conventional sequence asserts that the synthesis of PGE2 is effected in the POA via catalysis by COX-2 and mPGES-1 PMID: 15967158,5284360 Vane demonstrated that aspirin blocks prostaglandin synthesis
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c117 : 1
stoichiometry:c118 : 1
m18*0.1
nodelay
--
0
PMID: 15967158,9453538,1570314,7631045,10223523 Moreover, the transcription and translation of inducible COX-2 and mPGES-1 by inflammatory stimuli, LPS and IL-1beta alike, require at least 1 h in vitro
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c119 : 1
stoichiometry:c120 : 1
m19*0.1
nodelay
--
0
PMID: 15967158,9453538,1570314,7631045,10223523 Moreover, the transcription and translation of inducible COX-2 and mPGES-1 by inflammatory stimuli, LPS and IL-1beta alike, require at least 1 h in vitro
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c26 : 1
stoichiometry:c30 : 1
m15*0.1
nodelay
--
0
PMID:15967158 They are then released into the bloodstream and transported to sites in or close to the POA that react to their stimulation by selectively expressing COX-2 and mPGES-1.
p50
p50
cso30:i:ME_UnknownProduction
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c123 : 1
stoichiometry:c125 : 1
stoichiometry:c124 : 1
m32*0.1
nodelay
--
0
PMID: 15967158,14977603,15492017,11262580,15353338,15373964 the consensus has now developed that the febrile response to LPS (and also to live bacteria is probably not initiated by newly generated, blood-borne pyrogenic cytokines, but rather by the production of PGE2 directly stimulated in the periphery by the exogenous pyrogens themselves PMID: 15967158,5284360 Vane demonstrated that aspirin blocks prostaglandin synthesis
p51
p51
cso30:i:ME_ChangeInMaterialConcentration
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c126 : 1
stoichiometry:c128 : 1
stoichiometry:c129 : 1
stoichiometry:c130 : 1
stoichiometry:c127 : 1
m6*0.1
nodelay
--
0
PMID: 15967158 In conscious guinea pigs, Tc and plasma PGE2 rise simultaneously and concurrently with the first appearance in Kc of i.v. or i.p. injected LPS. PMID: 15967158,9100920,9608013,10600909 The associated Kc uptake of i.v. or i.p. LPS, the rise in plasma PGE2 and the febrile response are prevented by pre-treatment with gadolinium chloride, an agent that temporarily depletes Kc, or with CVF, a decomplementing toxin PMID: 15967158 Pre-treatment with PGE2 anti-serum (which does not cross the BBB) reduces the rises in Tc and plasma and preoptic PGE2 induced by i.v. LPS in conscious guinea pigs
p52
p52
cso30:i:ME_UnknownProduction
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c131 : 1
stoichiometry:c134 : 1
stoichiometry:c151 : 1
stoichiometry:c132 : 1
m36*m3590*0.1
nodelay
--
0
PMID: 15967158 The addition of serum C alone or in combination with LPS, but not of LPS alone, to primary Kc from guinea pigs and mice in vitro provokes the virtually immediate, near-maximal release of PGE2 by these cells; this response is catalyzed nondifferentially by COX-1 and COX-2 (constitutive in Kc).
p52
p53
cso30:i:ME_UnknownProduction
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c133 : 1
stoichiometry:c135 : 1
stoichiometry:c152 : 1
stoichiometry:c136 : 1
m36*m2122*0.1
nodelay
--
0
PMID: 15967158 The addition of serum C alone or in combination with LPS, but not of LPS alone, to primary Kc from guinea pigs and mice in vitro provokes the virtually immediate, near-maximal release of PGE2 by these cells; this response is catalyzed nondifferentially by COX-1 and COX-2 (constitutive in Kc).
p52
p54
cso30:i:ME_UnknownProduction
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c137 : 1
stoichiometry:c138 : 1
stoichiometry:c139 : 1
stoichiometry:c150 : 1
stoichiometry:c140 : 1
m36*m6*m3590*0.1
nodelay
--
0
PMID: 15967158 The addition of serum C alone or in combination with LPS, but not of LPS alone, to primary Kc from guinea pigs and mice in vitro provokes the virtually immediate, near-maximal release of PGE2 by these cells; this response is catalyzed nondifferentially by COX-1 and COX-2 (constitutive in Kc).
p52
p55
cso30:i:ME_UnknownProduction
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c141 : 1
stoichiometry:c142 : 1
stoichiometry:c143 : 1
stoichiometry:c153 : 1
stoichiometry:c144 : 1
m2122*m6*m36*0.1
nodelay
--
0
PMID: 15967158 The addition of serum C alone or in combination with LPS, but not of LPS alone, to primary Kc from guinea pigs and mice in vitro provokes the virtually immediate, near-maximal release of PGE2 by these cells; this response is catalyzed nondifferentially by COX-1 and COX-2 (constitutive in Kc).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c145 : 1
stoichiometry:c146 : 1
stoichiometry:c147 : 1
m37*m38*0.1
nodelay
--
0
PMID: 15967158,4145320 NE also stimulates the release of PGE2 in brain tissue in vitro
p57
p57
cso30:i:ME_UnknownProduction
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c148 : 1
stoichiometry:c149 : 1
m39*0.1
nodelay
--
0
PMID: 15967158,4145320 NE also stimulates the release of PGE2 in brain tissue in vitro PMID: 15967158,5284360 Vane demonstrated that aspirin blocks prostaglandin synthesis
p6
p6
cso30:i:ME_Binding
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c13 : 1
stoichiometry:c14 : 1
stoichiometry:c15 : 1
m3096*m871*0.1
nodelay
--
0
PMID:15967158 They are then released into the bloodstream and transported to sites in or close to the POA that react to their stimulation by selectively expressing COX-2 and mPGES-1.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c25 : 1
stoichiometry:c29 : 1
m17*0.1
nodelay
--
0
PMID:15967158 They are then released into the bloodstream and transported to sites in or close to the POA that react to their stimulation by selectively expressing COX-2 and mPGES-1.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c16 : 1
stoichiometry:c17 : 1
stoichiometry:c18 : 1
m1591*m12*0.1
nodelay
--
0
PMID:15967158 They are then released into the bloodstream and transported to sites in or close to the POA that react to their stimulation by selectively expressing COX-2 and mPGES-1.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c19 : 1
stoichiometry:c20 : 1
stoichiometry:c21 : 1
m230*m14*0.1
nodelay
--
0
PMID:15967158 They are then released into the bloodstream and transported to sites in or close to the POA that react to their stimulation by selectively expressing COX-2 and mPGES-1.
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--